Sökning: id:"swepub:oai:DiVA.org:uu-517191" >
p53 stabilisation p...
p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts
-
- Berglund, Hanna (författare)
- Uppsala universitet,Cancerprecisionsmedicin
-
- Lundsten Salomonsson, Sara (författare)
- Uppsala universitet,Cancerprecisionsmedicin,Ridgeview Instruments AB, SE-752 38, Uppsala, Sweden
-
- Mohajershojai, Tabassom (författare)
- Uppsala universitet,Cancerprecisionsmedicin
-
visa fler...
-
Ferrer Gago, Fernando Jose (författare)
-
- Lane, David P. (författare)
- Uppsala universitet,Institutionen för immunologi, genetik och patologi,p53Lab, Agency for Science Technology and Research (A*STAR), Singapore, 138648, Singapore; Department of Microbiology, Tumour and Cell Biology, Karolinska Institute, SE-171 65, Solna, Sweden
-
- Nestor, Marika, 1976- (författare)
- Uppsala universitet,Cancerprecisionsmedicin
-
visa färre...
-
(creator_code:org_t)
- 2023
- 2023
- Engelska.
-
Ingår i: European Journal of Nuclear Medicine and Molecular Imaging. - : Springer. - 1619-7070 .- 1619-7089.
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- PurposeMolecular radiotherapy is a treatment modality that is highly suitable for targeting micrometastases and [177Lu]Lu-DOTATATE is currently being explored as a potential novel treatment option for high-risk neuroblastoma. p53 is a key player in the proapoptotic signalling in response to radiation-induced DNA damage and is therefore a potential target for radiosensitisation.MethodsThis study investigated the use of the p53 stabilising peptide VIP116 and [177Lu]Lu-DOTATATE, either alone or in combination, for treatment of neuroblastoma tumour xenografts in mice. Initially, the uptake of [177Lu]Lu-DOTATATE in the tumours was confirmed, and the efficacy of VIP116 as a monotherapy was evaluated. Subsequently, mice with neuroblastoma tumour xenografts were treated with placebo, VIP116, [177Lu]Lu-DOTATATE or a combination of both agents.ResultsThe results demonstrated that monotherapy with either VIP116 or [177Lu]Lu-DOTATATE significantly prolonged median survival compared to the placebo group (90 and 96.5 days vs. 50.5 days, respectively). Notably, the combination treatment further improved median survival to over 120 days. Furthermore, the combination group exhibited the highest percentage of complete remission, corresponding to a twofold increase compared to the placebo group. Importantly, none of the treatments induced significant nephrotoxicity. Additionally, the therapies affected various molecular targets involved in critical processes such as apoptosis, hypoxia and angiogenesis.ConclusionIn conclusion, the combination of VIP116 and [177Lu]Lu-DOTATATE presents a promising novel treatment approach for neuroblastoma. These findings hold potential to advance research efforts towards a potential cure for this vulnerable patient population.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Radiologi och bildbehandling (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Radiology, Nuclear Medicine and Medical Imaging (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Neuroblastoma
- Molecular radiotherapy
- p53
- [177Lu]Lu-DOTATATE
- Radiosensitisation
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas